U.S. researchers reported seeking patent protection for methods to neutralize circulating tumor cells (CTCs) during hemodialysis to prevent cancer metastasis and reduce cancer-related deaths.
Shanghai Yingli Pharmaceutical Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Fudan University has patented compounds acting as microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) inhibitors and proprotein convertase subtilisin/kexin-type 9 (PCSK9) degradation inducers reported to be useful for the treatment of alopecia, atherosclerosis, cancer, Alzheimer’s disease, pulmonary fibrosis, hyperlipidemia, keratosis and obesity, among others.
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified histamine H3 receptor antagonists reported to be useful for the treatment of pain, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, obesity, eating disorder, neuropathic pain and itching.
Researchers from Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome and Noonan syndrome.
Shenzhen Targetrx Biotechnology Co. Ltd. has disclosed cycloalkyl or heterocyclyl substituted heteroaryl compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy and autoimmune disease.
Inventors from the International School of Advanced Studies (SISSA) in Trieste, Italy reported filing a patent for a graphene-based device for the targeted mucosal and transmucosal delivery and/or controlled release of active pharmaceutical ingredients (APIs) for various therapeutic applications when on-demand drug administration is needed.
Shanghai Zhigen Pharmaceutical Technology Co. Ltd. has identified aminoketone compounds with improved chemical stability that are potentially useful for the treatment of depression, post-traumatic stress, obsessive-compulsive disorder, pain and anxiety disorders.
Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections.
Research at Baruch S Blumberg Institute has led to the discovery of new diazepine derivatives targeting yellow fever virus nonstructural protein 4B (NS4B) for the treatment of yellow fever virus infections.
RSS
